Premature ovarian insufficiency (POI) is a clinically heterogeneous disorder characterized by ovarian dysfunction occurring before the age of 40, leading to infertility and increased long-term health risks. Current management strategies alleviate symptoms but fail to restore ovarian function or fertility, thereby prompting an urgent demand for regenerative therapies for POI. Mesenchymal stromal cells (MSCs) have emerged as a promising regenerative strategy due to their multifunctional capabilities, including paracrine effects, immunomodulation, and cytoprotection effects. This review systematically synthesizes preclinical and clinical evidence supporting the efficacy of MSCs in mitigating ovarian damage, enhancing folliculogenesis, restoring hormonal balance, and promoting the restoration of fertility in both POI models and patients. In addition, this article examines ongoing challenges, such as cellular heterogeneity, the determination of optimal transplantation strategies, and ensuring long-term safety. It also highlights innovative approaches, including biomaterial-enhanced transplantation, genetic engineering, and exosome-based therapies. The integration of these advanced strategies within personalized medicine frameworks holds significant potential to transform the clinical management of POI.
Impact Statement
Mesenchymal stromal cells (MSCs) have emerged as a promising therapeutic strategy for premature ovarian insufficiency (POI) due to their potential to restore impaired ovarian tissue function. This work systematically reviews the literature on MSC-based therapies for POI, encompassing aspects from underlying mechanisms to clinical applications, and consolidates evidence supporting the efficacy of MSCs. Furthermore, this paper examines the current challenges and future developmental trajectories in this domain, aiming to provide a comprehensive reference for future research and clinical management of POI.
Menopause Subgroup, Chinese Society of Obstetrics and Gynecology CMA. [Consensus of clinical diagnosis and treatment of premature ovarian insufficiency (2023)]. Zhonghua Fu Chan Ke Za Zhi, 2023; 58(10):721–728; doi: 10.3760/cma.j.cn112141-20230316-00122
RoseBI, BrownSE. An explanation of the mechanisms underlying fragile X-associated premature ovarian insufficiency. J Assist Reprod Genet, 2020; 37(6):1313–1322; doi: 10.1007/s10815-020-01774-x
5.
RosarioR, AndersonR. The molecular mechanisms that underlie fragile X-associated premature ovarian insufficiency: Is it RNA or protein based? Mol Hum Reprod, 2020; 26(10):727–737; doi: 10.1093/molehr/gaaa057
6.
SharifK, WatadA, BridgewoodC, KanducD, AmitalH, ShoenfeldY. Insights into the autoimmune aspect of premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab, 2019; 33(6):101323; doi: 10.1016/j.beem.2019.101323
7.
HeWB, DuJ, YangXW, et al.Novel inactivating mutations in the FSH receptor cause premature ovarian insufficiency with resistant ovary syndrome. Reprod Biomed Online, 2019; 38(3):397–406; doi: 10.1016/j.rbmo.2018.11.011
8.
ChenW, XuX, WangL, BaiG, XiangW. Low expression of Mfn2 is associated with mitochondrial damage and apoptosis of ovarian tissues in the premature ovarian failure model. PLoS One, 2015; 10(9):e0136421; doi: 10.1371/journal.pone.0136421
9.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022; 29(7):767–794; doi: 10.1097/GME.0000000000002028
10.
CraciunasL, ZdoukopoulosN, VinayagamS, MohiyiddeenL. Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency. Cochrane Database Syst Rev, 2022; 10(10):CD008209; doi: 10.1002/14651858.CD008209.pub2
11.
GonçalvesCR, VasconcellosAS, RodriguesTR, CominFV, ReisFM. Hormone therapy in women with premature ovarian insufficiency: A systematic review and meta-analysis. Reprod Biomed Online, 2022; 44(6):1143–1157; doi: 10.1016/j.rbmo.2022.02.006
12.
MaunderA, VermeulenN, VincentAJ, PanayN, EeC. Complementary therapies for women with premature ovarian insufficiency: A systematic literature review to inform the 2024 update of the ESHRE/ASRM/IMS/CRE-WHiRL guidelines on premature ovarian insufficiency. Climacteric, 2025:1–9; doi: 10.1080/13697137.2025.2530441 Published online
13.
SullivanSD, SarrelPM, NelsonLM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril, 2016; 106(7):1588–1599; doi: 10.1016/j.fertnstert.2016.09.046
14.
XuL, LiuY, SunY, et al.Tissue source determines the differentiation potentials of mesenchymal stem cells: A comparative study of human mesenchymal stem cells from bone marrow and adipose tissue. Stem Cell Res Ther, 2017; 8(1):275; doi: 10.1186/s13287-017-0716-x
15.
Nombela-ArrietaC, RitzJ, SilbersteinLE. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol, 2011; 12(2):126–131; doi: 10.1038/nrm3049
16.
CaplanAI, CorreaD. The MSC: An injury drugstore. Cell Stem Cell, 2011; 9(1):11–15; doi: 10.1016/j.stem.2011.06.008
PriesterC, MacDonaldA, DharM, BowA. Examining the characteristics and applications of mesenchymal, induced pluripotent, and embryonic stem cells for tissue engineering approaches across the germ layers. Pharmaceuticals (Basel), 2020; 13(11):344; doi: 10.3390/ph13110344
19.
BarlowS, BrookeG, ChatterjeeK, et al.Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev, 2008; 17(6):1095–1107; doi: 10.1089/scd.2007.0154
20.
HassR, KasperC, BöhmS, JacobsR. Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 2011; 9:12; doi: 10.1186/1478-811X-9-12
21.
ShiY, HuG, SuJ, et al.Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell Res, 2010; 20(5):510–518; doi: 10.1038/cr.2010.44
22.
KarpJM, Leng TeoGS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell, 2009; 4(3):206–216; doi: 10.1016/j.stem.2009.02.001
23.
SquillaroT, PelusoG, GalderisiU. Clinical trials with mesenchymal stem cells: An update. Cell Transplant, 2016; 25(5):829–848; doi: 10.3727/096368915X689622
24.
UllahM, LiuDD, ThakorAS. Mesenchymal stromal cell homing: Mechanisms and strategies for improvement. iScience, 2019; 15:421–438; doi: 10.1016/j.isci.2019.05.004
25.
GaoF, ChiuSM, MotanDAL, et al.Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis, 2016; 7(1):e2062; doi: 10.1038/cddis.2015.327
McGlacken-ByrneSM, ConwayGS. Premature ovarian insufficiency. Best Pract Res Clin Obstet Gynaecol, 2022; 81:98–110; doi: 10.1016/j.bpobgyn.2021.09.011
28.
CaplanAI. Mesenchymal stem cells: Time to change the name!. Stem Cells Transl Med, 2017; 6(6):1445–1451; doi: 10.1002/sctm.17-0051
29.
LaiRC, ArslanF, LeeMM, et al.Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res, 2010; 4(3):214–222; doi: 10.1016/j.scr.2009.12.003
30.
PanayN, AndersonRA, NappiRE, et al.Premature ovarian insufficiency: An International Menopause Society white paper. Climacteric, 2020; 23(5):426–446; doi: 10.1080/13697137.2020.1804547
31.
RahmanR, PanayN. Diagnosis and management of premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab, 2021; 35(6):101600; doi: 10.1016/j.beem.2021.101600
32.
GolezarS, Ramezani TehraniF, KhazaeiS, EbadiA, KeshavarzZ. The global prevalence of primary ovarian insufficiency and early menopause: A meta-analysis. Climacteric, 2019; 22(4):403–411; doi: 10.1080/13697137.2019.1574738
33.
LiM, ZhuY, WeiJ, ChenL, ChenS, LaiD. The global prevalence of premature ovarian insufficiency: A systematic review and meta-analysis. Climacteric, 2023; 26(2):95–102; doi: 10.1080/13697137.2022.2153033
34.
HuhtaniemiI, HovattaO, La MarcaA, et al.Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol Metab, 2018; 29(6):400–419; doi: 10.1016/j.tem.2018.03.010
35.
TuckerEJ, GroverSR, BachelotA, TouraineP, SinclairAH. Premature ovarian insufficiency: New Perspectives on genetic cause and phenotypic spectrum. Endocr Rev, 2016; 37(6):609–635; doi: 10.1210/er.2016-1047
36.
GorsiB, HernandezE, MooreMB, et al.Causal and candidate gene variants in a large cohort of women with primary ovarian insufficiency. J Clin Endocrinol Metab, 2022; 107(3):685–714; doi: 10.1210/clinem/dgab775
37.
GuoT, LiuH, XuB, et al.Epidemiology, genetic etiology and intervention of premature ovarian insufficiency. Endocr Rev, 2025; 46(5):621–651; doi: 10.1210/endrev/bnaf011Published online
38.
JaillardS, BellK, AkloulL, et al.New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing. Maturitas, 2020; 141:9–19; doi: 10.1016/j.maturitas.2020.06.004
VogtEC, RealFG, HusebyeES, et al.Premature menopause and autoimmune primary ovarian insufficiency in two international multi-center cohorts. Endocr Connect, 2022; 11(5):e220024; doi: 10.1530/EC-22-0024
44.
PodfigurnaA, StellmachA, SzeligaA, CzyzykA, MeczekalskiB. Metabolic profile of patients with premature ovarian insufficiency. J Clin Med, 2018; 7(10):374; doi: 10.3390/jcm7100374
45.
RobevaR, ElenkovaA, KirilovG, ZacharievaS. Metabolic risk in patients with a diminished ovarian reserve and premature ovarian insufficiency. J Clin Med, 2024; 13(17):5105; doi: 10.3390/jcm13175105
46.
GiriR, VincentAJ. Prevalence and risk factors of premature ovarian insufficiency/early menopause. Semin Reprod Med, 2020; 38(4–05):237–246; doi: 10.1055/s-0040-1722317
47.
FerrariniE, RussoL, FruzzettiF, et al.Clinical characteristics and genetic analysis in women with premature ovarian insufficiency. Maturitas, 2013; 74(1):61–67; doi: 10.1016/j.maturitas.2012.09.017
48.
PastoreLM, ChristiansonMS, StellingJ, KearnsWG, SegarsJH. Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR. J Assist Reprod Genet, 2018; 35(1):17–23; doi: 10.1007/s10815-017-1058-4
49.
WebberL, DaviesM, AndersonR, et al.ESHRE guideline: Management of women with premature ovarian insufficiency. Hum Reprod, 2016; 31(5):926–937; doi: 10.1093/humrep/dew027
50.
GargN, SinclairDA. Oogonial stem cells as a model to study age-associated infertility in women. Reprod Fertil Dev, 2015; 27(6):969–974; doi: 10.1071/RD14461
51.
QiuY, LiJ, ZhangY, et al.Cistanche deserticola polysaccharides enhance female germline stem cell differentiation through BMP/SMAD signaling to mitigate premature ovarian failure. Int J Biol Macromol, 2025; 304(Pt 2):140848; doi: 10.1016/j.ijbiomac.2025.140848
52.
DalmanA, TotonchiM, Rezazadeh ValojerdiM. Human ovarian theca-derived multipotent stem cells have the potential to differentiate into oocyte-like cells in vitro. Cell J, 2019; 20(4):527–536; doi: 10.22074/cellj.2019.5651
53.
TianC, HeJ, AnY, et al.Bone marrow mesenchymal stem cells derived from juvenile macaques reversed ovarian ageing in elderly macaques. Stem Cell Res Ther, 2021; 12(1):460; doi: 10.1186/s13287-021-02486-4
54.
TianC, YeL, ZhaoX, ZhuX, XuJ, PanX. Umbilical cord mesenchymal stem cells: A novel approach to intervention of ovarian ageing. Regen Ther, 2024; 26:590–598; doi: 10.1016/j.reth.2024.08.006
55.
WangX, LiT, BaiX, ZhuY, ZhangM, WangL. Therapeutic prospect on umbilical cord mesenchymal stem cells in animal model with primary ovarian insufficiency: A meta-analysis. Front Med (Lausanne), 2023; 10:1211070; doi: 10.3389/fmed.2023.1211070
56.
LvX, GuanC, LiY, et al.Effects of single and multiple transplantations of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice. J Ovarian Res, 2021; 14(1):119; doi: 10.1186/s13048-021-00871-4
57.
LiuR, ZhangX, FanZ, et al.Human amniotic mesenchymal stem cells improve the follicular microenvironment to recover ovarian function in premature ovarian failure mice. Stem Cell Res Ther, 2019; 10(1):299; doi: 10.1186/s13287-019-1315-9
58.
GuoC, MaY, SituY, et al.Mesenchymal stem cells therapy improves ovarian function in premature ovarian failure: A systematic review and meta-analysis based on preclinical studies. Front Endocrinol (Lausanne), 2023; 14:1165574; doi: 10.3389/fendo.2023.1165574
59.
HuHQ, XinXY, ZhuYT, et al.Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics. World J Stem Cells, 2024; 16(1):1–6; doi: 10.4252/wjsc.v16.i1.1
60.
TrounsonA, McDonaldC. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell, 2015; 17(1):11–22; doi: 10.1016/j.stem.2015.06.007
61.
LaiD, WangF, YaoX, ZhangQ, WuX, XiangC. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. J Transl Med, 2015; 13:155; doi: 10.1186/s12967-015-0516-y
62.
GabrH, RatebMA, El SissyMH, Ahmed SeddiekH, Ali Abdelhameed GoudaS. The effect of bone marrow-derived mesenchymal stem cells on chemotherapy induced ovarian failure in albino rats. Microsc Res Tech, 2016; 79(10):938–947; doi: 10.1002/jemt.22725
63.
FengX, LingL, ZhangW, et al.Effects of human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation in situ on primary ovarian insufficiency in SD rats. Reprod Sci, 2020; 27(7):1502–1512; doi: 10.1007/s43032-020-00147-0
64.
LingL, FengX, WeiT, et al.Human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation improves ovarian function in rats with premature ovarian insufficiency (POI) at least partly through a paracrine mechanism. Stem Cell Res Ther, 2019; 10(1):46; doi: 10.1186/s13287-019-1136-x
DengT, HeJ, YaoQ, et al.Human umbilical cord mesenchymal stem cells improve ovarian function in chemotherapy-induced premature ovarian failure mice through inhibiting apoptosis and inflammation via a paracrine mechanism. Reprod Sci, 2021; 28(6):1718–1732; doi: 10.1007/s43032-021-00499-1
67.
DaiW, YangH, XuB, et al.Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) alleviate excessive autophagy of ovarian granular cells through VEGFA/PI3K/AKT/mTOR pathway in premature ovarian failure rat model. J Ovarian Res, 2023; 16(1):198; doi: 10.1186/s13048-023-01278-z
68.
El-DeranyMO, SaidRS, El-DemerdashE. Bone marrow-derived mesenchymal stem cells reverse radiotherapy-induced premature ovarian failure: Emphasis on signal integration of TGF-β, Wnt/β-catenin and Hippo pathways. Stem Cell Rev Rep, 2021; 17(4):1429–1445; doi: 10.1007/s12015-021-10135-9
69.
YangW, ZhangJ, XuB, et al.HucMSC-derived exosomes mitigate the age-related retardation of fertility in female mice. Mol Ther, 2020; 28(4):1200–1213; doi: 10.1016/j.ymthe.2020.02.003
70.
DingC, ZouQ, WangF, et al.Human amniotic mesenchymal stem cells improve ovarian function in natural aging through secreting hepatocyte growth factor and epidermal growth factor. Stem Cell Res Ther, 2018; 9(1):55; doi: 10.1186/s13287-018-0781-9
71.
JuW, ZhaoY, YuY, ZhaoS, XiangS, LianF. Mechanisms of mitochondrial dysfunction in ovarian aging and potential interventions. Front Endocrinol (Lausanne), 2024; 15:1361289; doi: 10.3389/fendo.2024.1361289
72.
HassanN, HusseinDM, MalakFA, et al.Mesenchymal stem cells: A therapeutic approach in fertility restoration in premature ovarian insufficiency. Stem Cell Rev Rep, 2025; 21(7):2089–2102; doi: 10.1007/s12015-025-10944-2
73.
WangL, MeiQ, XieQ, et al.A comparative study of Mesenchymal Stem Cells transplantation approach to antagonize age-associated ovarian hypofunction with consideration of safety and efficiency. J Adv Res, 2022; 38:245–259; doi: 10.1016/j.jare.2021.09.001
74.
XiongY, SiY, QuanR, et al.hUMSCs restore ovarian function in POI mice by regulating GSK3β-mediated mitochondrial dynamic imbalances in theca cells. Sci Rep, 2024; 14(1):19008; doi: 10.1038/s41598-024-69381-9
75.
FuY, KarbaatL, WuL, LeijtenJ, BothSK, KarperienM. Trophic effects of Mesenchymal Stem Cells in tissue regeneration. Tissue Eng Part B Rev, 2017; 23(6):515–528; doi: 10.1089/ten.teb.2016.0365
76.
HuangB, LuJ, DingC, ZouQ, WangW, LiH. Exosomes derived from human adipose mesenchymal stem cells improve ovary function of premature ovarian insufficiency by targeting SMAD. Stem Cell Res Ther, 2018; 9(1):216; doi: 10.1186/s13287-018-0953-7
77.
RenY, HeJ, WangX, LiangH, MaY. Exosomes from adipose-derived stem cells alleviate premature ovarian failure via blockage of autophagy and AMPK/mTOR pathway. PeerJ, 2023; 11:e16517; doi: 10.7717/peerj.16517
78.
LiZ, LiuY, TianY, et al.Human umbilical cord mesenchymal stem cell-derived exosomes improve ovarian function in natural aging by inhibiting apoptosis. Int J Mol Med, 2023; 52(4):94; doi: 10.3892/ijmm.2023.5297
79.
MiaoH, MiaoC, LiN, HanJ. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles harboring IGF-1 improve ovarian function of mice with premature ovarian insufficiency through the Nrf2/HO-1 pathway. J Ovarian Res, 2024; 17(1):224; doi: 10.1186/s13048-024-01536-8
80.
LiZ, ZhangM, ZhengJ, et al.Human umbilical cord mesenchymal stem cell-derived exosomes improve ovarian function and proliferation of premature ovarian insufficiency by regulating the Hippo signaling pathway. Front Endocrinol (Lausanne), 2021; 12:711902; doi: 10.3389/fendo.2021.711902
YangZ, DuX, WangC, et al.Therapeutic effects of human umbilical cord mesenchymal stem cell-derived microvesicles on premature ovarian insufficiency in mice. Stem Cell Res Ther, 2019; 10(1):250; doi: 10.1186/s13287-019-1327-5
83.
HongL, YanL, XinZ, et al.Protective effects of human umbilical cord mesenchymal stem cell-derived conditioned medium on ovarian damage. J Mol Cell Biol, 2020; 12(5):372–385; doi: 10.1093/jmcb/mjz105
84.
SongA, ZhangS, ZhaoX, et al.Exosomes derived from menstrual blood stromal cells ameliorated premature ovarian insufficiency and granulosa cell apoptosis by regulating SMAD3/AKT/MDM2/P53 pathway via delivery of thrombospondin-1. Biomed Pharmacother, 2023; 166:115319; doi: 10.1016/j.biopha.2023.115319
85.
LiQ, ZhangZ, ShiW, et al.Drug-free in vitro activation combined with ADSCs-derived exosomes restores ovarian function of rats with premature ovarian insufficiency. J Ovarian Res, 2024; 17(1):158; doi: 10.1186/s13048-024-01475-4
86.
ZhangQ, SunJ, HuangY, et al.Human amniotic epithelial cell-derived exosomes restore ovarian function by transferring MicroRNAs against apoptosis. Mol Ther Nucleic Acids, 2019; 16:407–418; doi: 10.1016/j.omtn.2019.03.008
87.
LuY, WeiY, ShenX, et al.Human umbilical cord mesenchymal stem cell-derived extracellular vesicles improve ovarian function in rats with primary ovarian insufficiency by carrying miR-145-5p. J Reprod Immunol, 2023; 158:103971; doi: 10.1016/j.jri.2023.103971
88.
ZhangX, MaL, LiuX, et al.Sustained release of miR-21 carried by mesenchymal stem cell-derived exosomes from GelMA microspheres inhibits ovarian granulosa cell apoptosis in premature ovarian insufficiency. Mater Today Bio, 2025; 31:101469; doi: 10.1016/j.mtbio.2025.101469
89.
QuQ, LiuL, CuiY, et al.miR-126-3p containing exosomes derived from human umbilical cord mesenchymal stem cells promote angiogenesis and attenuate ovarian granulosa cell apoptosis in a preclinical rat model of premature ovarian failure. Stem Cell Res Ther, 2022; 13(1):352; doi: 10.1186/s13287-022-03056-y
90.
Rezaei-KiasariZ, ZamaniyanM, KhodashenasS, et al.The first case report of a pregnancy after exosome therapy in diminished ovarian reserve patient. International Journal of Clinical and Medical Case Reports, 2024; 5(6).
91.
ParkHS, ChughRM, SeokJ, et al.Comparison of the therapeutic effects between stem cells and exosomes in primary ovarian insufficiency: As promising as cells but different persistency and dosage. Stem Cell Res Ther, 2023; 14(1):165; doi: 10.1186/s13287-023-03397-2
92.
TakeharaY, YabuuchiA, EzoeK, et al.The restorative effects of adipose-derived mesenchymal stem cells on damaged ovarian function. Lab Invest, 2013; 93(2):181–193; doi: 10.1038/labinvest.2012.167
93.
LiJ, MaoQ, HeJ, SheH, ZhangZ, YinC. Human umbilical cord mesenchymal stem cells improve the reserve function of perimenopausal ovary via a paracrine mechanism. Stem Cell Res Ther, 2017; 8(1):55; doi: 10.1186/s13287-017-0514-5
94.
AhmedAI, DowidarMF, NegmAF, et al.Bone marrow mesenchymal stem cells expressing Neat-1, Hotair-1, miR-21, miR-644, and miR-144 subsided cyclophosphamide-induced ovarian insufficiency by remodeling the IGF-1-kisspeptin system, ovarian apoptosis, and angiogenesis. J Ovarian Res, 2024; 17(1):184; doi: 10.1186/s13048-024-01498-x
95.
CuiL, BaoH, ZhuW, et al.hUMSCs transplantation regulates AMPK/NR4A1 signaling axis to inhibit ovarian fibrosis in POI rats. Stem Cell Rev Rep, 2023; 19(5):1449–1465; doi: 10.1007/s12015-022-10469-y
96.
CuiL, BaoH, LiuZ, et al.hUMSCs regulate the differentiation of ovarian stromal cells via TGF-β(1)/Smad3 signaling pathway to inhibit ovarian fibrosis to repair ovarian function in POI rats. Stem Cell Res Ther, 2020; 11(1):386; doi: 10.1186/s13287-020-01904-3
97.
YamchiNN, RahbarghaziR, BedateAM, MahdipourM, NouriM, KhanbabaeeR. Menstrual blood CD146(+) mesenchymal stem cells reduced fibrosis rate in the rat model of premature ovarian failure. Cell Biochem Funct, 2021; 39(8):998–1008; doi: 10.1002/cbf.3669
98.
ZhangS, HuangB, SuP, et al.Concentrated exosomes from menstrual blood-derived stromal cells improves ovarian activity in a rat model of premature ovarian insufficiency. Stem Cell Res Ther, 2021; 12(1):178; doi: 10.1186/s13287-021-02255-3
99.
ZhangC, YuD, MeiY, et al.Single-cell RNA sequencing of peripheral blood reveals immune cell dysfunction in premature ovarian insufficiency. Front Endocrinol (Lausanne), 2023; 14:1129657; doi: 10.3389/fendo.2023.1129657
100.
LiuJ, WangL, ZhongW, et al.Single-Cell RNA sequencing reveals peripheral immune cell senescence and inflammatory phenotypes in patients with premature ovarian failure. J Inflamm Res, 2025; 18:2699–2715; doi: 10.2147/JIR.S496130
LiuS, WangT, LiuY, et al.Human placental mesenchymal stem cells ameliorates premature ovarian insufficiency via modulating gut microbiota and suppressing the inflammation in rats. PLoS One, 2025; 20(3):e0313763; doi: 10.1371/journal.pone.0313763
103.
LuX, CuiJ, CuiL, et al.The effects of human umbilical cord-derived mesenchymal stem cell transplantation on endometrial receptivity are associated with Th1/Th2 balance change and uNK cell expression of uterine in autoimmune premature ovarian failure mice. Stem Cell Res Ther, 2019; 10(1):214; doi: 10.1186/s13287-019-1313-y
104.
PuX, ZhangL, ZhangP, et al.Human UC-MSC-derived exosomes facilitate ovarian renovation in rats with chemotherapy-induced premature ovarian insufficiency. Front Endocrinol (Lausanne), 2023; 14:1205901; doi: 10.3389/fendo.2023.1205901
105.
ZhangL, SunY, ZhangXX, et al.Comparison of CD146 +/− mesenchymal stem cells in improving premature ovarian failure. Stem Cell Res Ther, 2022; 13(1):267; doi: 10.1186/s13287-022-02916-x
106.
WangZ, WeiQ, WangH, et al.Mesenchymal stem cell therapy using human umbilical cord in a rat model of autoimmune-induced premature ovarian failure. Stem Cells Int, 2020; 2020:3249495; doi: 10.1155/2020/3249495
107.
SongD, ZhongY, QianC, et al.Human umbilical cord mesenchymal stem cells therapy in cyclophosphamide-induced premature ovarian failure rat model. Biomed Res Int, 2016; 2016:2517514; doi: 10.1155/2016/2517514
108.
CaiJ, LiangX, SunY, BaoS. Beneficial effects of human umbilical cord mesenchymal stem cell (HUCMSC) transplantation on cyclophosphamide (CTX)-induced premature ovarian failure (POF) in Tibetan miniature pigs. Transpl Immunol, 2024; 84:102051; doi: 10.1016/j.trim.2024.102051
SunB, MaY, WangF, HuL, SunY. miR-644-5p carried by bone mesenchymal stem cell-derived exosomes targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. Stem Cell Res Ther, 2019; 10(1):360; doi: 10.1186/s13287-019-1442-3
111.
YangM, LinL, ShaC, et al.Bone marrow mesenchymal stem cell-derived exosomal miR-144-5p improves rat ovarian function after chemotherapy-induced ovarian failure by targeting PTEN. Lab Invest, 2020; 100(3):342–352; doi: 10.1038/s41374-019-0321-y
112.
AiG, MengM, GuoJ, et al.Adipose-derived stem cells promote the repair of chemotherapy-induced premature ovarian failure by inhibiting granulosa cells apoptosis and senescence. Stem Cell Res Ther, 2023; 14(1):75; doi: 10.1186/s13287-023-03297-5
113.
YinN, WuC, QiuJ, et al.Protective properties of heme oxygenase-1 expressed in umbilical cord mesenchymal stem cells help restore the ovarian function of premature ovarian failure mice through activating the JNK/Bcl-2 signal pathway-regulated autophagy and upregulating the circulating of CD8(+)CD28(-) T cells. Stem Cell Res Ther, 2020; 11(1):49; doi: 10.1186/s13287-019-1537-x
114.
LuX, BaoH, CuiL, et al.hUMSC transplantation restores ovarian function in POI rats by inhibiting autophagy of theca-interstitial cells via the AMPK/mTOR signaling pathway. Stem Cell Res Ther, 2020; 11(1):268; doi: 10.1186/s13287-020-01784-7
115.
DingC, ZouQ, WuY, et al.EGF released from human placental mesenchymal stem cells improves premature ovarian insufficiency via NRF2/HO-1 activation. Aging (Albany NY), 2020; 12(3):2992–3009; doi: 10.18632/aging.102794
116.
HuangB, QianC, DingC, MengQ, ZouQ, LiH. Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1. Stem Cell Res Ther, 2019; 10(1):362; doi: 10.1186/s13287-019-1490-8
117.
WuPL, TangSH, WangHY, et al.Human umbilical cord mesenchymal stem cells improve the ovarian function through oxidative stress-mediated PERK/eIF-2α/ATF4/CHOP signaling in premature ovarian insufficiency mice. Mol Biol Rep, 2024; 52(1):85; doi: 10.1007/s11033-024-10189-1
118.
JalaliL, AllahveisieA, RezaeiS, et al.Effect of preconditioning of human umbilical cord mesenchymal stem cells with hydrogen peroxide on the therapeutic potential of MSCs in the cyclophosphamide -induced premature ovarian failure mice model. Taiwan J Obstet Gynecol, 2023; 62(5):667–676; doi: 10.1016/j.tjog.2023.07.007
119.
DingC, ZhuL, ShenH, et al.Exosomal miRNA-17-5p derived from human umbilical cord mesenchymal stem cells improves ovarian function in premature ovarian insufficiency by regulating SIRT7. Stem Cells, 2020; 38(9):1137–1148; doi: 10.1002/stem.3204
120.
DingC, QianC, HouS, et al.Exosomal miRNA-320a is released from hAMSCs and regulates SIRT4 to prevent reactive oxygen species generation in POI. Mol Ther Nucleic Acids, 2020; 21:37–50; doi: 10.1016/j.omtn.2020.05.013
121.
DaiW, XuB, DingL, et al.Human umbilical cord mesenchymal stem cells alleviate chemotherapy-induced premature ovarian insufficiency mouse model by suppressing ferritinophagy-mediated ferroptosis in granulosa cells. Free Radic Biol Med, 2024; 220:1–14; doi: 10.1016/j.freeradbiomed.2024.04.229
122.
ChenJ, HeZ, XuW, et al.Human umbilical cord mesenchymal stem cells restore chemotherapy-induced premature ovarian failure by inhibiting ferroptosis in vitro ovarian culture system. Reprod Biol Endocrinol, 2024; 22(1):137; doi: 10.1186/s12958-024-01310-x
123.
ZhouY, HuangJ, ZengL, et al.Human mesenchymal stem cells derived exosomes improve ovarian function in chemotherapy-induced premature ovarian insufficiency mice by inhibiting ferroptosis through Nrf2/GPX4 pathway. J Ovarian Res, 2024; 17(1):80; doi: 10.1186/s13048-024-01403-6
124.
MoJ, HuH, LiP, et al.Human hair follicle-derived mesenchymal stem cells improve ovarian function in cyclophosphamide-induced POF mice. Stem Cell Res Ther, 2025; 16(1):67; doi: 10.1186/s13287-024-04097-1
125.
ChenL, WuY, LvT, TuoR, XiaoY. Mesenchymal stem cells enchanced by salidroside to inhibit ferroptosis and improve premature ovarian insufficiency via Keap1/Nrf2/GPX4 signaling. Redox Rep, 2025; 30(1):2455914; doi: 10.1080/13510002.2025.2455914
126.
EdessyM, HosniHN, ShadyY, WafY, BakrS, KamelM. Autologous stem cells therapy, the first baby of idiopathic premature ovarian failure. Acta Med Int, 2016; 3(1):19–23.
127.
GuptaS, LodhaP, KarthickMS, TandulwadkarSR. Role of autologous bone marrow-derived stem cell therapy for follicular recruitment in premature ovarian insufficiency: Review of literature and a case report of world’s first baby with ovarian autologous stem cell therapy in a perimenopausal woman of age 45 year. J Hum Reprod Sci, 2018; 11(2):125–130; doi: 10.4103/jhrs.JHRS_57_18
128.
IgboeliP, El AndaloussiA, SheikhU, et al.Intraovarian injection of autologous human mesenchymal stem cells increases estrogen production and reduces menopausal symptoms in women with premature ovarian failure: Two case reports and a review of the literature. J Med Case Rep, 2020; 14(1):108; doi: 10.1186/s13256-020-02426-5
129.
TinjićS, AbazovićD, LjubićD, et al.Influence of autologous in vitro activation of ovaries by stem cells and growth factors on endocrine and reproductive function of patients with ovarian insufficiency-A clinical trial study. Int J Fertil Steril, 2021; 15(3):178–188; doi: 10.22074/IJFS.2020.134678
130.
DingL, YanG, WangB, et al.Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with long history of infertility. Sci China Life Sci, 2018; 61(12):1554–1565; doi: 10.1007/s11427-017-9272-2
131.
YanL, WuY, LiL, et al.Clinical analysis of human umbilical cord mesenchymal stem cell allotransplantation in patients with premature ovarian insufficiency. Cell Prolif, 2020; 53(12):e12938; doi: 10.1111/cpr.12938
132.
MashayekhiM, MirzadehE, ChekiniZ, et al.Evaluation of safety, feasibility and efficacy of intra-ovarian transplantation of autologous adipose derived mesenchymal stromal cells in idiopathic premature ovarian failure patients: Non-randomized clinical trial, phase I, first in human. J Ovarian Res, 2021; 14(1):5; doi: 10.1186/s13048-020-00743-3
133.
HuangC, KongN, XueP, et al.Transplantation of UC-MSCs in ovary improves ovarian function and intermediate outcomes in IVF/ICSI cycles of POI patients: A clinical cohort study. Stem Cell Res Ther, 2025; 16(1):552; doi: 10.1186/s13287-025-04680-0
HongliYan. Clinical study on the safety and efficacy of human amniotic mesenchymal stem cells in the treatment of premature ovarian insufficiency. https://clinicaltrials.gov/study/NCT07115082
ZhangY, LiuH, LouY, et al.Efficacy and safety of autologous adipose tissue-derived stromal vascular fraction in patients with premature ovarian insufficiency: Protocol for a single-centre randomised controlled trial. BMJ Open, 2025; 15(4):e093804; doi: 10.1136/bmjopen-2024-093804
140.
UmerA, AhmadK, KhanN, GreeneDL, ShamimS, HabibaUE. Meta-analysis highlight the therapeutic potential of stem cells for premature ovarian failure. Regen Ther, 2024; 26:478–488; doi: 10.1016/j.reth.2024.07.001
141.
WangMY, WangYX, Li-LingJ, XieHQ. Adult Stem cell therapy for premature ovarian failure: From bench to bedside. Tissue Eng Part B Rev, 2022; 28(1):63–78; doi: 10.1089/ten.TEB.2020.0205
142.
ZhuangWZ, LinYH, SuLJ, et al.Mesenchymal stem/stromal cell-based therapy: Mechanism, systemic safety and biodistribution for precision clinical applications. J Biomed Sci, 2021; 28(1):28; doi: 10.1186/s12929-021-00725-7
YuanZ, ZhangY, HeX, et al.Engineering mesenchymal stem cells for premature ovarian failure: Overcoming challenges and innovating therapeutic strategies. Theranostics, 2024; 14(17):6487–6515; doi: 10.7150/thno.102641
145.
DaiW, YangH, XuB, et al.3D hUC-MSC spheroids exhibit superior resistance to autophagy and apoptosis of granulosa cells in POF rat model. Reproduction, 2024; 168(2):e230496; doi: 10.1530/REP-23-0496
146.
BijonowskiBM, YuanX, JeskeR, LiY, GrantSC. Cyclical aggregation extends in vitro expansion potential of human mesenchymal stem cells. Sci Rep, 2020; 10(1):20448; doi: 10.1038/s41598-020-77288-4
147.
HafiziM, HajarizadehA, AtashiA, et al.Nanochelating based nanocomplex, GFc7, improves quality and quantity of human mesenchymal stem cells during in vitro expansion. Stem Cell Res Ther, 2015; 6:226; doi: 10.1186/s13287-015-0216-9
148.
WangJ, ZhangJ, ZhangX, ZhouH. A protein-based hydrogel for in vitro expansion of mesenchymal stem cells. PLoS One, 2013; 8(9):e75727; doi: 10.1371/journal.pone.0075727
149.
SippD, RobeyPG, TurnerL. Clear up this stem-cell mess. Nature, 2018; 561(7724):455–457; doi: 10.1038/d41586-018-06756-9
SuJ, DingL, ChengJ, et al.Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency. Hum Reprod, 2016; 31(5):1075–1086; doi: 10.1093/humrep/dew041
152.
YangY, LeiL, WangS, et al.Transplantation of umbilical cord-derived mesenchymal stem cells on a collagen scaffold improves ovarian function in a premature ovarian failure model of mice. In Vitro Cell Dev Biol Anim, 2019; 55(4):302–311; doi: 10.1007/s11626-019-00337-4
153.
ZhouY, ZhouJ, XuX, et al.Matrigel/umbilical cord-derived mesenchymal stem cells promote granulosa cell proliferation and ovarian vascularization in a mouse model of premature ovarian failure. Stem Cells Dev, 2021; 30(15):782–796; doi: 10.1089/scd.2021.0005
154.
LarondaMM, RutzAL, XiaoS, et al.A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice. Nat Commun, 2017; 8:15261; doi: 10.1038/ncomms15261
155.
YangY, ZhaoH, WuM, et al.3D-printed scaffolds with controlled-releasing compounds for ectopic activation of dormant ovarian follicles. IJB, 2025; 11(1):246–258.
156.
ChenS, WangT, ChenJ, et al.3D bioprinting technology innovation in female reproductive system. Mater Today Bio, 2025; 31:101551; doi: 10.1016/j.mtbio.2025.101551
157.
YiH, LeeG, ParkS, et al.Reconstructing the female reproductive system using 3D bioprinting in tissue engineering. Mater Today Bio, 2025; 34:102127; doi: 10.1016/j.mtbio.2025.102127
158.
ChristoffersS, SeilerL, WiebeE, BlumeC. Possibilities and efficiency of MSC co-transfection for gene therapy. Stem Cell Res Ther, 2024; 15(1):150; doi: 10.1186/s13287-024-03757-6
159.
NiX, OuC, GuoJ, et al.Lentiviral vector-mediated co-overexpression of VEGF and Bcl-2 improves mesenchymal stem cell survival and enhances paracrine effects in vitro. Int J Mol Med, 2017; 40(2):418–426; doi: 10.3892/ijmm.2017.3019
160.
XiuG, LiX, YinY, et al.SDF-1/CXCR4 augments the therapeutic effect of bone marrow mesenchymal stem cells in the treatment of lipopolysaccharide-induced liver injury by promoting their migration through PI3K/Akt signaling pathway. Cell Transplant, 2020; 29:963689720929992; doi: 10.1177/0963689720929992
161.
LingL, HouJ, LiuD, et al.Important role of the SDF-1/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI). Stem Cell Res Ther, 2022; 13(1):79; doi: 10.1186/s13287-022-02759-6
162.
TanC, TanS, ZhangH, et al.Enhanced migration and immunoregulatory capacity of BMSCs mediated by overexpression of CXCR4 and IL-35. Mol Immunol, 2022; 150:1–8; doi: 10.1016/j.molimm.2022.07.005
163.
MishraP, SivakumarA, JohnsonA, et al.Gene editing improves endoplasmic reticulum-mitochondrial contacts and unfolded protein response in Friedreich’s ataxia iPSC-derived neurons. Front Pharmacol, 2024; 15:1323491; doi: 10.3389/fphar.2024.1323491
164.
WangR, LiuF, LiaoQ, WuJ, WangL, LiK. Precision medicine in premature ovarian insufficiency: A focus on the precision therapeutic strategies for mesenchymal stem cells. Stem Cell Res Ther, 2025; 16(1):381; doi: 10.1186/s13287-025-04512-1
